NEWS CENTER - In the research of the Cancer Research UK, it was revealed that the vaccine reduced the cases of cervical cancer by 90 percent within the scope of the HPV vaccine program launched in 2008.

 

In a research conducted by Cancer Research UK, it was stated that within the scope of the HPV (human papillomavirus) vaccine program launched in England in 2008, the vaccine reduced cervical cancer cases by approximately 90 percent.

 

It is estimated to prevent the formation of 17.200 cancers

 

In the statement made by Cancer Research UK, it was stated that the vaccine reduced the rate of cervical cancer by almost 90 percent in women who were vaccinated at the age of 11-13 and are now in their 20s. Researchers estimate that the HPV vaccination program prevents about 450 cervical cancers and 17.200 cancer formation. It also stated that the HPV vaccination program for young women was launched in the country in 2008, and for the ‘first time’ a study has shown that ‘it works and will save lives’.

 

‘The results are hopeful’

 

It was expressed that the work, which was also published in the refereed medical journal, is the first of its kind to focus on the England vaccine program and is the first to analyze the effectiveness of the bivalent cervical cancer vaccine (Ceravix). It was also announced that the team examined all cervical cancers diagnosed in women aged 20-64 years in the UK between January 2006 and June 2019, and the results ‘look hopeful’. It was announced that the vaccine reduces the rate of cervical cancer by 34 percent in those vaccinated between the ages of 16-18, by 62 percent in those aged 14-16, and by 90 percent in those vaccinated between the ages of 12-13.

It was also mentioned that almost all cervical cancers are caused by HPV and this tie was proven more than 20 years ago by Cancer Research UK scientists. It was stated that the HPV vaccine provides protection against the main cancer-causing strains of the virus (HPV 16 and 18).